Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use; Technical Amendment, 12730 [E7-4957]
Download as PDF
<![CDATA[
12730
Federal Register / Vol. 72, No. 52 / Monday, March 19, 2007 / Rules and Regulations
automatically take effect at the end of 45
days of continuous session of Congress
beginning on October 12, 2006. The 45day review period ended on February
16, 2007. This document confirms the
effective date as February 16, 2007.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Effective Date: The final rule
published on October 12, 2006 (71 FR
60055) took effect on February 16, 2007.
[Docket No. 1976N–0052G] (formerly Docket
No. 76N–052G)
DATES:
FOR FURTHER INFORMATION CONTACT:
Becky Shortland, Gray’s Reef National
Marine Sanctuary, 10 Ocean Science
Circle, Savannah, Georgia 31411; 912–
598–2381; Becky.Shortland@noaa.gov.
(Federal Domestic Assistance Catalog
Number 11.429 Marine Sanctuary Program)
Dated: March 13, 2007.
John H. Dunnigan,
Assistant Administrator for Ocean Services
and Coastal Zone Management.
[FR Doc. 07–1303 Filed 3–16–07; 8:45 am]
Food and Drug Administration
21 CFR Part 341
Cold, Cough, Allergy, Bronchodilator,
and Antiasthmatic Drug Products for
Over-the-Counter Human Use;
Technical Amendment
AGENCY:
Food and Drug Administration,
HHS.
Final rule; technical
amendment.
ACTION:
Revised Medical Criteria for
Determination of Disability,
Musculoskeletal System and Related
Criteria
CFR Correction
SUPPLEMENTARY INFORMATION:
SOCIAL SECURITY ADMINISTRATION
20 CFR Part 416
In Title 20 of the Code of Federal
Regulations, Parts 400 to 499, revised as
of April 1, 2006, on page 948, § 416.933
is corrected by adding a sentence after
the second sentence to read as follows:
§ 416.933 How we make a finding of
presumptive disability or presumptive
blindness.
* * * For other impairments, a
finding of disability or blindness must
be based on medical evidence or other
information that, though not sufficient
for a formal determination of disability
or blindness, is sufficient for us to find
that there is a high degree of probability
that you are disabled or blind. * * *
[FR Doc. 07–55503 Filed 3–16–07; 8:45 am]
BILLING CODE 1505–01–D
SUMMARY:
FDA
published the final monograph (FM) for
cold, cough, allergy, bronchodilator, and
antiasthmatic combination drug
products for OTC human use in the
Federal Register of December 23, 2002
(67 FR 78158). In that FM, FDA
inadvertently added § 341.40 (21 CFR
341.40) to subpart C of the monograph,
when that section should have been
added to subpart B of the monograph.
Accordingly, FDA is now moving
§ 341.40 from subpart C to subpart B of
the monograph.
Publication of this document
constitutes final action on this change
under the Administrative Procedure Act
(5 U.S.C. 553). Notice and public
procedures are unnecessary because
FDA is merely implementing a change
in the location of a section in an OTC
drug monograph. No other changes are
being made to that section of the
monograph.
cprice-sewell on PROD1PC66 with RULES
List of Subjects in 21 CFR Part 341
Labeling, Over-the-counter drugs.
I Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs, 21 CFR part 341 is
amended as follows:
VerDate Aug<31>2005
15:36 Mar 16, 2007
Jkt 211001
1. The authority citation for 21 CFR
part 341 continues to read as follows:
I
The Food and Drug
Administration (FDA) is amending its
regulations to change the location of a
section in an over-the-counter (OTC)
drug monograph. This action is editorial
in nature and is intended to improve the
accuracy of the agency’s regulations.
DATES: This rule is effective March 19,
2007.
FOR FURTHER INFORMATION CONTACT:
Gerald M. Rachanow, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, rm. 5496,
Silver Spring, MD 20993, 301–796–
2090.
BILLING CODE 3510–08–M
PART 341—COLD, COUGH, ALLERGY,
BRONCHODILATOR, AND
ANTIASTHMATIC DRUG PRODUCTS
FOR OVER-THE-COUNTER HUMAN
USE
PO 00000
Frm 00030
Fmt 4700
Sfmt 4700
Authority: 21 U.S.C. 321, 351, 352, 353,
355, 360, 371.
Subpart B—Active Ingredients
[Amended]
2. Remove § 341.40 Permitted
combinations of active ingredients from
subpart C and add it to subpart B of part
341.
I
Dated: March 12, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–4957 Filed 3–16–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF THE TREASURY
31 CFR Part 103
RIN 1506–AA83
Financial Crimes Enforcement
Network; Amendment to the Bank
Secrecy Act Regulations—Imposition
of Special Measure Against Banco
Delta Asia, Including Its Subsidiaries
Delta Asia Credit Limited and Delta
Asia Insurance Limited, as a Financial
Institution of Primary Money
Laundering Concern
Financial Crimes Enforcement
Network, Department of the Treasury.
ACTION: Final rule.
AGENCY:
SUMMARY: The Financial Crimes
Enforcement Network (‘‘FinCEN’’) is
issuing a final rule imposing a special
measure against Banco Delta Asia SARL
(‘‘Banco Delta Asia’’ or ‘‘the bank’’) as
a financial institution of primary money
laundering concern, pursuant to the
authority contained in 31 U.S.C. 5318A
of the Bank Secrecy Act.
DATES: This final rule is effective on
April 18, 2007.
FOR FURTHER INFORMATION CONTACT:
Regulatory Policy and Programs
Division, Financial Crimes Enforcement
Network, (800) 949–2732.
SUPPLEMENTARY INFORMATION:
I. Background
A. Statutory Provisions
On October 26, 2001, the President
signed into law the Uniting and
Strengthening America by Providing
Appropriate Tools Required To
E:\FR\FM\19MRR1.SGM
19MRR1
]]>Agencies
[Federal Register Volume 72, Number 52 (Monday, March 19, 2007)]
[Rules and Regulations]
[Page 12730]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-4957]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 341
[Docket No. 1976N-0052G] (formerly Docket No. 76N-052G)
Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug
Products for Over-the-Counter Human Use; Technical Amendment
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule; technical amendment.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is amending its
regulations to change the location of a section in an over-the-counter
(OTC) drug monograph. This action is editorial in nature and is
intended to improve the accuracy of the agency's regulations.
DATES: This rule is effective March 19, 2007.
FOR FURTHER INFORMATION CONTACT: Gerald M. Rachanow, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 22, rm. 5496, Silver Spring, MD 20993, 301-796-
2090.
SUPPLEMENTARY INFORMATION: FDA published the final monograph (FM) for
cold, cough, allergy, bronchodilator, and antiasthmatic combination
drug products for OTC human use in the Federal Register of December 23,
2002 (67 FR 78158). In that FM, FDA inadvertently added Sec. 341.40
(21 CFR 341.40) to subpart C of the monograph, when that section should
have been added to subpart B of the monograph. Accordingly, FDA is now
moving Sec. 341.40 from subpart C to subpart B of the monograph.
Publication of this document constitutes final action on this
change under the Administrative Procedure Act (5 U.S.C. 553). Notice
and public procedures are unnecessary because FDA is merely
implementing a change in the location of a section in an OTC drug
monograph. No other changes are being made to that section of the
monograph.
List of Subjects in 21 CFR Part 341
Labeling, Over-the-counter drugs.
0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs, 21 CFR part
341 is amended as follows:
PART 341--COLD, COUGH, ALLERGY, BRONCHODILATOR, AND ANTIASTHMATIC
DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE
0
1. The authority citation for 21 CFR part 341 continues to read as
follows:
Authority: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371.
Subpart B--Active Ingredients [Amended]
0
2. Remove Sec. 341.40 Permitted combinations of active ingredients
from subpart C and add it to subpart B of part 341.
Dated: March 12, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7-4957 Filed 3-16-07; 8:45 am]
BILLING CODE 4160-01-S
